Cardiol Therapeutics (CRDL) Cash from Investing Activities (2020 - 2026)

Cardiol Therapeutics (CRDL) has 7 years of Cash from Investing Activities data on file, last reported at -$34699.3 in Q1 2026.

• Quarterly Cash from Investing Activities fell 317.03% year-over-year to -$34699.3 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$43753.7 (down 105.63% YoY) and the FY2025 annual result came in at -$17557.1, down 15.2% from the prior year.
• Cash from Investing Activities retreated to -$34699.3 in Q1 2026, from -$2214.4 in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of -$1669.1 in Q2 2022 to a low of -$35236.5 in Q4 2022.
• A 5-year average of -$10082.5 and a median of -$4647.1 in 2025 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2024 — Cash from Investing Activities soared 92.14% — and 2026, when it sank 317.03%.
• Tracing CRDL's Cash from Investing Activities over 5 years: stood at -$35236.5 in 2022, then surged by 77.68% to -$7863.9 in 2023, then surged by 43.94% to -$4408.9 in 2024, then surged by 49.78% to -$2214.4 in 2025, then slumped by 1467.01% to -$34699.3 in 2026.
• The last three Cash from Investing Activities figures came in at -$34699.3 (Q1 2026), -$2214.4 (Q4 2025), and -$2193.0 (Q3 2025), per Business Quant data.